Aberrant miRNAs expressed in HER-2 negative breast cancers patient.

CONCLUSION: The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients' prognosis or response to therapy. PMID: 30342533 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30342533?dopt=Abstract

Source: Clinical Genitourinary Cancer - October 20, 2018 Category: Cancer & Oncology Authors: Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I Tags: J Exp Clin Cancer Res Source Type: research